User login
Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.
Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.
Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.
Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.
Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570
Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.
Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.
Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.
Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.
Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570
Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.
Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.
Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.
Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.
Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570